An interventional study of Pulsed Radiofrequency and Conventional Radiofrequency in Back Pain, sponsored by Adana City Training and Research Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Adana City Training and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Back Pain with a site in Turkey — 9 open to participants now, 11 under way, none of them phase 3. Back Pain · Turkey.
Among the 57 studies in Back Pain with a site in Turkey, this one is the 6th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 33 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 51st registered.
729 studies on the registry are indexed under Back Pain; 110 are open to participants now.
Browse Back Pain studies →9 of the 57 studies in Back Pain with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 18–65
Konya Beyhekim Training and Research Hospital · Sites in Turkey
Ages 18+
Hacettepe University · Sites in Turkey
Ages 18+
Atılım University · Sites in Turkey
Ages 18–50 · Healthy volunteers
Izmir Democracy University · Sites in Turkey
Ages 18–35 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 90 is above the median of 70 across 594 interventional studies indexed under Back Pain.
Median enrollment 55 across the 34 interventional studies, 110 across the 23 observational. Of the 38 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 57 has an industry lead sponsor. The 10 most frequent:
Adana City Training and Research Hospital is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Adana City Training and Research Hospital has 1 study filed under Back Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Back Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07550569Baskent UniversityEffectiveness of High Intensity Laser Therapy in Management of Lumbar Disc Herniation | 2026-11-30 |
| NCT07497269Adana City Training and Research HospitalConventional vs Pulsed RF in Coccydynia | 2027-04-01 |
| NCT07633730Marmara UniversityEfficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis | 2027-05-02 |
| NCT06825650Hacettepe UniversityInvestigation of the Cultural Adaptation, Validity, and Reliability of the Turkish Version of the CAP Questionnaire | 2027-11-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 57 studies in Back Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to prospectively evaluate the effects of pulsed and conventional radiofrequency ablation of the ganglion impar on pain, quality of life, and sleep quality in patients with refractory coccydynia, and to determine whether one treatment is superior to the other.
Coccydynia, commonly referred to as tailbone pain, is a persistent pain condition targeting the coccyx, a small triangular bone located at the lower end of the spine. The main cause of this pain is usually abnormal movement in the coccygeal region, which leads to continuous inflammation. Coccydynia more commonly affects women than men and is often associated with obesity. Although it most frequently occurs around the age of 40, it can be seen in individuals of all ages. The origins of coccydynia are varied, including both physical and psychological factors. The main physical causes are trauma from falling onto the buttocks, repetitive minor injuries, or childbirth, which are the most common triggers. Non-traumatic causes of coccydynia include degenerative diseases of the joints or discs, abnormal movements in the sacrococcygeal joint, obesity, infections, changes in the shape of the coccyx, or cancers in the pelvic or anorectal regions. The effectiveness of treatments for coccydynia varies considerably.
Several conservative treatment options exist for coccydynia, such as nonsteroidal anti-inflammatory drugs (NSAIDs), local analgesics, hot or cold applications, transcutaneous electrical nerve stimulation (TENS), specially designed wedge-shaped cushions (coccygeal cushions), and exercises aimed at relaxing the levator ani muscle. These methods aim to reduce pain and inflammation and improve the functionality of the coccyx and surrounding muscles. When these conservative approaches fail to provide relief, more invasive procedures may be considered. Techniques such as direct local anesthetic injections to the coccyx, coccygeal nerve blocks, caudal epidural injections, and ganglion impar blocks offer minimally invasive alternatives for coccydynia treatment. Among the methods for impar ganglion blocks, pulsed RF, thermocoagulation ablation techniques, and neurolytic techniques are considered treatments that provide long-term pain palliation. The transacrococcygeal technique for impar ganglion block is an easy and safe method. This technique allows neurolysis or radiofrequency thermocoagulation ablation of the impar ganglion and can be used for diagnostic blocks depending on the response to initial diagnostic injections.
The ganglion impar (Walther ganglion) is a single sympathetic ganglion formed by the convergence of the distal ends of the lumbosacral sympathetic chains. It is the lowest ganglion of the sympathetic nervous system. Being single and medial (unlike the paired paravertebral sympathetic ganglia), it is the only solitary sympathetic ganglion. It is located retroperitoneally, anterior to the sacrum, at the level of the sacrococcygeal symphysis, and posterior to the rectum. It provides sympathetic efferent fibers and receives afferent sensory information from many pelvic structures, supplying sympathetic and nociceptive innervation to the perineum, coccyx, anus, distal rectum, vulva, urethra, and vagina. Interventions on the ganglion impar disrupt afferent sympathetic and nociceptive pathways from the pelvis, perineum, and anal region. Interventions on the ganglion impar can be performed using various agents and techniques, including local anesthetics, corticosteroids, ethanol, phenol, botulinum toxin, radiofrequency ablation (RFA) or modulation (RFM), and cryoablation. The transsacrococcygeal technique is more commonly used. Numerous technique variations exist, but the goal is to successfully direct the needle to the anterior surface of the coccyx or sacrococcygeal symphysis to deliver local anesthetics, steroids, or neurolytic agents without damaging pelvic bones or organs. Radiopaque contrast is injected to visualize proper retroperitoneal distribution of the agent along the anterior surface of the coccyx.
Visceral pain mediated by sympathetic fibers in the perineal region can be effectively treated by neurolysis of the impar ganglion. Theoretically, this procedure can also be applied for pain due to malignancy, endometriosis, complex regional pain syndrome, prostate pain, radiation-induced enteritis, postherpetic neuralgia, and refractory coccydynia. The use of sympathetic chain ablation for persistent pain in the sacral-pelvic region differs from other targets, because the anatomical variation of the impar ganglion requires careful combination of radiofrequency thermocoagulation and neurolytic agents (alcohol or phenol) to maximize pain control. When using the thermocoagulation radiofrequency ablation technique, special equipment such as electrostimulation devices and minute controllers are required. Therefore, selective destruction of nerve fibers is possible, and the size and location of the lesion can be controlled, resulting in a lower risk of complications.
The effects of conventional radiofrequency (CRF) thermocoagulation for chronic coccydynia were retrospectively analyzed (patients unresponsive to conservative treatment and local injections for 6 months. Ten patients who responded to diagnostic block with 10 mL of 0.25% bupivacaine underwent CRF treatment. Approximately 90% of patients achieved successful results at 6 months, defined as a 50% reduction in VAS scores. Transcoccygeal/intercoccygeal CRF of the ganglion impar is simple, relatively safe, and should be considered for chronic coccydynia unresponsive to conservative therapy for 6 months. Similar findings were observed by another study in a retrospective analysis of CRF in 20 patients with chronic refractory coccydynia.
No previous study has compared the superiority of these two routinely applied long-term coccyx pain treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiofrequency ablation is performed on the ganglion impar using a 22G needle with a 10 mm active tip. Tissue impedance and motor/sensory responses are checked before ablation. Pulsed RFA is applied at 42 °C for 4 minutes. Pulsed RF treatments will be applied to patients only once, and pain, disability, sleep quality, and patient satisfaction will be assessed before treatment and at 1, 3, 6, and 12 months after the procedure
Procedure: Pulsed Radiofrequency
Conventional RF treatments will be applied to patients only once, and pain, disability, sleep quality, and patient satisfaction will be assessed before treatment and at 1, 3, 6, and 12 months after the procedure Radiofrequency ablation is performed on the ganglion impar using a 22G needle with a 10 mm active tip. Tissue impedance and motor/sensory responses are checked before ablation. Conventional RFA is applied for two cycles of 90 seconds at 80 °C.
Procedure: Conventional Radiofrequency
Once the needle is properly positioned along the sacrococcygeal disc line, 1 mL of radiopaque contrast is injected. The needle placement is confirmed in the lateral fluoroscopic view as a comma-shaped spread in the retroperitoneal space. Radiofrequency interventions on the ganglion impar are performed using a radiofrequency generator. A 22G radiofrequency needle (0.7×98.6 mm) with a 10 mm exposed active tip is used. Before performing the ablation, tissue impedance and motor and sensory responses (motor and sensory stimulation) are checked. The expected tissue impedance is \<500 ohms. Sensory paresthesia at \<1 V and 50 Hz is observed around the sacrococcygeal region. Pulsed RFA is applied at 42 °C for 4 minutes after stimulation.
Once the needle is properly positioned along the sacrococcygeal disc line, 1 mL of radiopaque contrast is injected. The needle placement is confirmed in the lateral fluoroscopic view as a comma-shaped spread in the retroperitoneal space. Radiofrequency interventions on the ganglion impar are performed using a radiofrequency generator. A 22G radiofrequency needle (0.7×98.6 mm) with a 10 mm exposed active tip is used. Before performing the ablation, tissue impedance and motor and sensory responses (motor and sensory stimulation) are checked. The expected tissue impedance is \<500 ohms. Sensory paresthesia at \<1 V and 50 Hz is observed around the sacrococcygeal region. Neuroablation is applied for 2 cycles of 90 seconds at 80 °C.
The Numeric Rating Scale (NRS)
Pain intensity was assessed using the Numeric Rating Scale (NRS), a linear pain scale ranging from 0 (no pain) to 10 (the worst imaginable pain)."
Time frame: From enrollment to the end of treatment at 12th months
Oswestry Disability Index (ODI)
Oswestry Disability Index (ODI): The ODI is a self-reported measure used to assess the extent to which a patient's daily activities are limited. It is one of the most commonly used tools in clinical research and routine patient follow-up to determine the level of functional disability. General Characteristics: The index consists of 10 sections, each scored from 0 to 5 (0: no difficulty, 5: maximum difficulty). The maximum raw score is 50, and the total score is multiplied by 2 to convert it to a percentage (0-100%). Assessment Categories (approximate): 0-20%: Minimal disability (the patient can continue daily activities and perform most tasks). 21-40%: Moderate disability. 41-60%: Severe disability (pain significantly affects daily life). 61-80%: Crippling disability (the patient is unable to perform many activities). 81-100%: Bed-bound or completely dependent, unable to maintain an active lifestyle.
Time frame: From enrollment to the end of treatment at 12th months
Pittsburgh Sleep Quality Index (PSQI)
Pittsburgh Sleep Quality Index (PSQI): The PSQI includes 18 items that contribute to its scoring. It assesses seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Some components are represented by a single item, while others are calculated by grouping several items. Each item is scored from 0 to 3, and the sum of the seven component scores forms the total PSQI score. The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. A total PSQI score of ≤5 indicates "good sleep quality," whereas a score \>5 indicates "poor sleep quality."
Time frame: From enrollment to the end of treatment at 12 months
Global Perceived Effect (GPE)
Global Perceived Effect (GPE): The GPE measures the patient's perception of their condition compared to a previous period. It reflects the response to the question: "How do you feel now compared to before treatment?" At 1, 3, 6, and 12 months after treatment, the patient's overall perceived effect will be assessed using a 7-point Likert scale: 1. \- Much worse 2. \- Worse 3. \- Slightly worse 4. \- No change 5. \- Slightly better 6. \- Better 7. \- Much better Patients reporting "much better" (score = 7) or "better" (score = 6) will be considered satisfied with the procedure.
Time frame: From enrollment to the end of treatment at 12th months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data will not be shared to ensure the confidentiality and privacy of the patients, in accordance with ethical approval and local regulations
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 259 non-industry interventional studies with no phase under Back Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 33. This study's planned 12 months is close to that.
Counting every sponsor, half of 294 studies reached it within 13 months; a quarter within 5 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adana City Training and Research Hospital